• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成人中的腺病毒特异性T细胞很常见,对常见的儿童腺病毒感染具有交叉反应性,并可被腺病毒载体疫苗增强。

Adenovirus-Specific T Cells in Adults Are Frequent, Cross-Reactive to Common Childhood Adenovirus Infections and Boosted by Adenovirus-Vectored Vaccines.

作者信息

Mukhopadhyay Rookmini, Lambisia Arnold W, Hoang Jennifer P, Ravenhill Benjamin J, Agoti Charles N, Krishna Benjamin A, Houldcroft Charlotte J

机构信息

Department of Genetics, University of Cambridge, Cambridge, UK.

Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.

出版信息

J Med Virol. 2025 Feb;97(2):e70222. doi: 10.1002/jmv.70222.

DOI:10.1002/jmv.70222
PMID:39921609
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11806872/
Abstract

Human adenoviruses (HAdVs) cause diverse disease presentations as pathogens and are also used as viral vectors for vaccines and gene therapy products. Pre-existing adaptive immune responses to HAdV are known to influence symptom severity, viral clearance and the success of viral vectored products. Of note, approximately 50% of the UK's adult population has received at least one dose of a chimpanzee adenovirus vectored SARS-CoV-2 vaccine (ChAdOx1) since January 2021. We used FluoroSpot analysis to quantify the interferon-gamma (IFNγ) and interleukin-2 (IL2) responses of healthy blood donors to HAdV species A, B, C, D and F and chimpanzee adenovirus Y25, related to HAdV species E. We find that cellular immune responses to multiple species of human adenovirus are ubiquitous among healthy adult blood donors and that stimulating PBMC with whole hexon peptide libraries induces a significantly greater IFNγ and IL2 response than using selected peptide pools alone. We then compared the cellular immune responses of ChAdOx1 recipients and control donors using PBMC collected in 2021 and found that homotypic and heterotypic IFNγ responses were significantly boosted in ChAdOx1 recipients but not controls. Finally, we show that in PBMC derived from blood donors, IFNγ responses are made to both conserved and variable regions of the hexon protein. Future vaccination campaigns using adenoviral vectored vaccines will need to account for the pre-existing exposure of recipients to both circulating HAdVs and vaccines such as ChAdOx1, which convey polyfunctional antiviral T cell responses to even low seroprevalence HAdV types.

摘要

人类腺病毒(HAdVs)作为病原体可导致多种疾病表现,同时也被用作疫苗和基因治疗产品的病毒载体。已知对HAdV预先存在的适应性免疫反应会影响症状严重程度、病毒清除以及病毒载体产品的成功率。值得注意的是,自2021年1月以来,英国约50%的成年人口已接种至少一剂黑猩猩腺病毒载体的SARS-CoV-2疫苗(ChAdOx1)。我们使用FluoroSpot分析来量化健康献血者对HAdV A、B、C、D和F型以及与HAdV E型相关的黑猩猩腺病毒Y25的干扰素-γ(IFNγ)和白细胞介素-2(IL2)反应。我们发现,健康成年献血者中对多种人类腺病毒的细胞免疫反应普遍存在,并且用完整六邻体肽文库刺激外周血单个核细胞(PBMC)所诱导的IFNγ和IL2反应明显大于仅使用选定肽库的情况。然后,我们使用在2021年收集的PBMC比较了ChAdOx1接种者和对照献血者的细胞免疫反应,发现ChAdOx1接种者的同型和异型IFNγ反应显著增强,而对照者则不然。最后,我们表明,在来自献血者的PBMC中,对六邻体蛋白的保守区和可变区均产生了IFNγ反应。未来使用腺病毒载体疫苗的疫苗接种活动将需要考虑接种者预先接触过循环中的HAdV以及诸如ChAdOx1等疫苗的情况,这些疫苗会对即使血清阳性率较低的HAdV类型产生多功能抗病毒T细胞反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2a/11806872/9bd603217d3b/JMV-97-e70222-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2a/11806872/47acca8a77fe/JMV-97-e70222-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2a/11806872/499d6f231454/JMV-97-e70222-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2a/11806872/ef9d330f3f73/JMV-97-e70222-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2a/11806872/0cce2a869d81/JMV-97-e70222-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2a/11806872/149e39b8d24a/JMV-97-e70222-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2a/11806872/9bd603217d3b/JMV-97-e70222-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2a/11806872/47acca8a77fe/JMV-97-e70222-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2a/11806872/499d6f231454/JMV-97-e70222-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2a/11806872/ef9d330f3f73/JMV-97-e70222-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2a/11806872/0cce2a869d81/JMV-97-e70222-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2a/11806872/149e39b8d24a/JMV-97-e70222-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d2a/11806872/9bd603217d3b/JMV-97-e70222-g001.jpg

相似文献

1
Adenovirus-Specific T Cells in Adults Are Frequent, Cross-Reactive to Common Childhood Adenovirus Infections and Boosted by Adenovirus-Vectored Vaccines.成人中的腺病毒特异性T细胞很常见,对常见的儿童腺病毒感染具有交叉反应性,并可被腺病毒载体疫苗增强。
J Med Virol. 2025 Feb;97(2):e70222. doi: 10.1002/jmv.70222.
2
Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice.用于增强小鼠抗SARS-CoV-2保护性免疫的黑猩猩ChAdOx1腺病毒载体疫苗的注意事项。
Appl Microbiol Biotechnol. 2024 Jan 27;108(1):179. doi: 10.1007/s00253-023-12927-0.
3
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.腺病毒载体新冠疫苗(ChAdOx1 nCoV-19)对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2)的安全性和免疫原性:一项 1/2 期、单盲、随机对照临床试验的初步报告。
Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20.
4
mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-γ and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity.信使核糖核酸疫苗诱导的严重急性呼吸综合征冠状病毒2刺突蛋白特异性γ干扰素和白细胞介素-2 T细胞反应可预测血清中和作用,并被预先存在的交叉反应性免疫短暂增强。
J Virol. 2025 Mar 18;99(3):e0168524. doi: 10.1128/jvi.01685-24. Epub 2025 Jan 31.
5
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.在一项 1/2 期临床试验中,单次接种 ChAdOx1 nCoV-19(AZD1222)疫苗诱导的 T 细胞和抗体反应。
Nat Med. 2021 Feb;27(2):270-278. doi: 10.1038/s41591-020-01194-5. Epub 2020 Dec 17.
6
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.基于复制缺陷型猴腺病毒载体 ChAdOx1 的疫苗:风险/收益评估的关键考虑因素标准化模板。
Vaccine. 2022 Aug 19;40(35):5248-5262. doi: 10.1016/j.vaccine.2022.06.008. Epub 2022 Jun 14.
7
Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls.与健康对照相比,免疫缺陷患者接种5剂严重急性呼吸综合征冠状病毒2(SARS-CoV-2)疫苗后T细胞免疫增强,体液反应降低。
Front Immunol. 2025 Mar 6;16:1538453. doi: 10.3389/fimmu.2025.1538453. eCollection 2025.
8
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.在年轻和老年成年人中进行的一次单盲、随机、对照、2/3 期试验中,观察 ChAdOx1 nCoV-19 疫苗在初免-加强免疫方案中的安全性和免疫原性(COV002)。
Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19.
9
Two Novel Adenovirus Vectors Mediated Differential Antibody Responses via Interferon-α and Natural Killer Cells.两种新型腺病毒载体通过干扰素-α和自然杀伤细胞介导差异化抗体应答。
Microbiol Spectr. 2023 Aug 17;11(4):e0088023. doi: 10.1128/spectrum.00880-23. Epub 2023 Jun 22.
10
Longitudinal Analysis of Binding Antibody Levels Against 39 Human Adenovirus Types in Sera from 60 Regular Blood Donors from Greifswald, Germany, over 5 Years from 2018 to 2022.2018年至2022年的5年间,对德国格赖夫斯瓦尔德60名定期献血者血清中针对39种人类腺病毒类型的结合抗体水平进行纵向分析。
Viruses. 2024 Nov 7;16(11):1747. doi: 10.3390/v16111747.

本文引用的文献

1
Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines.基于腺病毒的新冠疫苗中交叉反应性T细胞应答的鉴定
NPJ Vaccines. 2024 Jun 5;9(1):99. doi: 10.1038/s41541-024-00895-z.
2
The investigation of the dynamics of changes in neutralizing antibody titers against type 5 adenovirus in the context of vaccination against a new coronavirus infection.针对新型冠状病毒感染的疫苗接种背景下,5 型腺病毒中和抗体滴度变化的动力学研究。
Virology. 2024 Jun;594:110051. doi: 10.1016/j.virol.2024.110051. Epub 2024 Mar 8.
3
Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice.
用于增强小鼠抗SARS-CoV-2保护性免疫的黑猩猩ChAdOx1腺病毒载体疫苗的注意事项。
Appl Microbiol Biotechnol. 2024 Jan 27;108(1):179. doi: 10.1007/s00253-023-12927-0.
4
Identification of Large Adenovirus Infection Outbreak at University by Multipathogen Testing, South Carolina, USA, 2022.美国南卡罗来纳州通过多病原体检测鉴定大学腺病毒大规模感染暴发,2022 年。
Emerg Infect Dis. 2024 Feb;30(2):358-362. doi: 10.3201/eid3002.230623.
5
A Fulminant Case of Adenovirus Genotype C108 Infection in a Pediatric Stem Cell Transplant Recipient with x-Linked Lymphoproliferative Syndrome Type 1.X 连锁淋巴组织增生症 1 型患儿发生腺病毒基因型 C108 感染的暴发性病例
Viruses. 2024 Jan 18;16(1):137. doi: 10.3390/v16010137.
6
Familial CD45RA T cells to treat severe refractory infections in immunocompromised patients.利用家族性CD45RA T细胞治疗免疫功能低下患者的严重难治性感染。
Front Med (Lausanne). 2023 Feb 8;10:1083215. doi: 10.3389/fmed.2023.1083215. eCollection 2023.
7
Seroprevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Patients with Neuromuscular Disorders.神经肌肉疾病患者中针对 39 种人腺病毒类型的结合抗体和中和抗体的血清流行率。
Viruses. 2022 Dec 27;15(1):79. doi: 10.3390/v15010079.
8
Analysis of the Prevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Student Cohorts Reveals Low-Prevalence Types and a Decline in Binding Antibody Levels during the SARS-CoV-2 Pandemic.分析学生队列中对 39 种人腺病毒类型的结合和中和抗体的流行情况,揭示了低流行类型和 SARS-CoV-2 大流行期间结合抗体水平的下降。
J Virol. 2022 Nov 23;96(22):e0113322. doi: 10.1128/jvi.01133-22. Epub 2022 Nov 7.
9
Immunocompromised host section: Adoptive T-cell therapy for dsDNA viruses in allogeneic hematopoietic cell transplant recipients.免疫抑制宿主部分:同种异体造血细胞移植受者中针对双链 DNA 病毒的过继 T 细胞治疗。
Curr Opin Infect Dis. 2022 Aug 1;35(4):302-311. doi: 10.1097/QCO.0000000000000838. Epub 2022 Jul 5.
10
Evidence of previous SARS-CoV-2 infection in seronegative patients with long COVID.长新冠血清学阴性患者的既往 SARS-CoV-2 感染证据。
EBioMedicine. 2022 Jul;81:104129. doi: 10.1016/j.ebiom.2022.104129. Epub 2022 Jun 27.